Mohammad Rahmati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mohammad Rahmati has a total of 165 co-authors. Here are the top co-authors by number of shared publications:
- Abolfazl Akbarzadeh
Razi Drug Research Center Iran University of Medical Sciences Tehran Iran
7 shared publications Ali Mota
6 shared publicationsEffat Alizadeh
6 shared publications- Nosratollah Zarghami
Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
6 shared publications - Morteza Milani
Department of Medical Nanotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
5 shared publications - Alireza Alihemmati
Department of Anatomical Sciences, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
4 shared publications
Latest Publications
- 9 August 2026
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
Targeting p53/p21 Signaling: Linarin as a Novel Modulator of 5-FU Sensitization in Colorectal Cancer
Purpose: We assessed linarin, a plant-derived flavone glycoside, for its ability to overcome intrinsic 5-fluorouracil (5-FU) resistance by reinstating p53/p21-mediated tumor suppression in colorectal cancer (CRC) cell models, and we explicitly present these findings as a mechanistic proof of concept within a defined in vitro scope. Methods: Cell viability was measured using the MTT assay; synergy was assessed using the combination index (CI) with isobologram validation; and programmed cell death was evaluated by internucleosomal DNA fragmentation ELISA and Western blot analysis of caspase-dependent markers. Underlying pathways were probed by immunoblotting, quantitative RT-PCR, and targeted siRNA-mediated knockdown of p53 and p21, complemented by pharmacological inhibition with pifithrin-α and UC2288. Results: Linarin induced concentration-dependent cell killing in CRC lines, yielding IC₅₀ values of 122.8–210.2 μM at 48 hours, alongside selective sparing of normal colon cells (NCM460; selectivity index approximately 2.0–3.3-fold). The p53 status-dependent sensitivity gradient (HCT116 wild-type < SW480 mutant < HCT116 p53⁻/⁻) provided initial evidence of p53-dependent cytotoxicity. Dual therapy with 5-FU yielded robust synergy (CI 0.52–0.88) in p53-proficient lines, with near-additive effects in p53-null cells (CI 0.77), and notably reduced the 5-FU IC₅₀ in intrinsically resistant LoVo cells from 19.0 μM to 5.7 μM. Linarin promoted p53 stabilization and Ser15/Ser20 phosphorylation, elevated p21 mRNA levels to 5.4-fold the control level, and suppressed MDM2 mRNA levels to 0.42-fold the control level. This was accompanied by caspase-dependent cell death and amplified DNA damage signaling (elevated γ-H2AX). Functional validation via siRNA knockdown and pharmacological inhibition confirmed the centrality of the p53/p21 pathway in linarin's sensitizing action in p53-competent cells. Conclusion: As a mechanistic proof-of-concept, linarin demonstrates the capacity to potentiate 5-FU cytotoxicity by reactivating the p53/p21 pathway in CRC models harboring functional p53. Future investigations should prioritize models of acquired resistance and formulation optimization to advance these findings toward preclinical translation.
- 9 August 2026
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
Targeting p53/p21 Signaling: Linarin as a Novel Modulator of 5-FU Sensitization in Colorectal Cancer
Purpose: We assessed linarin, a plant-derived flavone glycoside, for its ability to overcome intrinsic 5-fluorouracil (5-FU) resistance by reinstating p53/p21-mediated tumor suppression in colorectal cancer (CRC) cell models, and we explicitly present these findings as a mechanistic proof of concept within a defined in vitro scope. Methods: Cell viability was measured using the MTT assay; synergy was assessed using the combination index (CI) with isobologram validation; and programmed cell death was evaluated by internucleosomal DNA fragmentation ELISA and Western blot analysis of caspase-dependent markers. Underlying pathways were probed by immunoblotting, quantitative RT-PCR, and targeted siRNA-mediated knockdown of p53 and p21, complemented by pharmacological inhibition with pifithrin-α and UC2288. Results: Linarin induced concentration-dependent cell killing in CRC lines, yielding IC₅₀ values of 122.8–210.2 μM at 48 hours, alongside selective sparing of normal colon cells (NCM460; selectivity index approximately 2.0–3.3-fold). The p53 status-dependent sensitivity gradient (HCT116 wild-type < SW480 mutant < HCT116 p53⁻/⁻) provided initial evidence of p53-dependent cytotoxicity. Dual therapy with 5-FU yielded robust synergy (CI 0.52–0.88) in p53-proficient lines, with near-additive effects in p53-null cells (CI 0.77), and notably reduced the 5-FU IC₅₀ in intrinsically resistant LoVo cells from 19.0 μM to 5.7 μM. Linarin promoted p53 stabilization and Ser15/Ser20 phosphorylation, elevated p21 mRNA levels to 5.4-fold the control level, and suppressed MDM2 mRNA levels to 0.42-fold the control level. This was accompanied by caspase-dependent cell death and amplified DNA damage signaling (elevated γ-H2AX). Functional validation via siRNA knockdown and pharmacological inhibition confirmed the centrality of the p53/p21 pathway in linarin's sensitizing action in p53-competent cells. Conclusion: As a mechanistic proof-of-concept, linarin demonstrates the capacity to potentiate 5-FU cytotoxicity by reactivating the p53/p21 pathway in CRC models harboring functional p53. Future investigations should prioritize models of acquired resistance and formulation optimization to advance these findings toward preclinical translation.
- Open Access
- 22 July 2026
- Published by Brieflands in Archives of Pediatric Infectious Diseases
- Vol. 15 (1) , e164216
Design and Evaluation of Innovative Loop-Mediated Isothermal Amplification-Lateral Flow Dipstick Kits for Advanced Detection of HPV16 and HPV18
Background: Cervical cancer is a major cause of cancer-related mortality among women worldwide. Existing human papillomavirus (HPV) detection methods, such as PCR and immunohistochemistry (IHC), face barriers related to cost, infrastructure, and accessibility. Loop-mediated isothermal amplification (LAMP), a rapid, thermocycler-free nucleic acid amplification technique, combined with lateral flow dipstick (LFD) readout, enables simple, visual DNA detection. Objectives: This study developed and evaluated a novel LAMP-LFD assay to improve the detection of high-risk HPV16/18 in clinical specimens, with the aim of providing a rapid, sensitive, and user-friendly diagnostic tool for use in local healthcare settings. Methods: Cervical specimens were collected from women attending a gynecology clinic who were clinically suspected of having HPV16/18 infection, and DNA was extracted. HPV16/18 presence was initially confirmed by real-time PCR, which served as the reference standard for HPV16/18 detection. Subsequently, LAMP reactions using HPV16/18-specific primers were performed, and amplification products were detected using a molecular LFD system with gold-labeled antibodies. The same DNA samples were then analyzed using the LAMP-LFD assay. The sensitivity and specificity of the LAMP-LFD assay were compared with those of standard PCR methods. Diagnostic performance (sensitivity, specificity, predictive values, accuracy, and Cohen's kappa) was calculated by comparing LAMP-LFD results with real-time PCR. Included samples had adequate volume and acceptable DNA purity (A260/280 ratio: 1.8 - 2). All participants provided written informed consent. Exclusion criteria included sample contamination, insufficient volume, low-quality DNA, lack of signed consent, or failure to meet quality control standards to ensure sample integrity and reproducibility. Agreement between the LAMP-LFD assay and PCR was assessed using Cohen’s kappa coefficient, with 95% confidence intervals calculated. Results: Among the 50 clinical specimens, real-time PCR identified 20 HPV-positive and 30 HPV-negative specimens. Compared with PCR, the LAMP-LFD assay detected all PCR-positive samples but yielded two false-positive results for HPV16, resulting in high sensitivity (100%) and good specificity (93.3%). The specificity of the LAMP-LFD assay was also high, with minimal cross-reactivity observed between HPV16 and HPV18 targets. Compared with conventional PCR, the LAMP-LFD assay provided a faster turnaround time, required less specialized equipment, and was suitable for point-of-care applications. The sensitivity of LAMP is similar to or better than that of PCR (101 to 103 copies). LAMP specificity varies (67.5%-99.2%) and can be lower than that of PCR. Overall, the LAMP-LFD assay demonstrated 100% sensitivity and 93.3% specificity compared with real-time PCR. Conclusions: The developed LAMP-LFD assay is a rapid, sensitive, and user-friendly method for detecting high-risk HPV16 and HPV18 genotypes in clinical specimens. This approach has the potential to enhance HPV screening and cervical cancer prevention, particularly in resource-limited settings where access to conventional molecular diagnostics is restricted. The implementation of LAMP-LFD technology could facilitate timely diagnosis and management of HPV-associated diseases in local hospitals and field studies.
- 22 July 2026
- Published by Brieflands in Archives of Pediatric Infectious Diseases
- Vol. 15 (1) , e164216
Open AccessDesign and Evaluation of Innovative Loop-Mediated Isothermal Amplification-Lateral Flow Dipstick Kits for Advanced Detection of HPV16 and HPV18
Background: Cervical cancer is a major cause of cancer-related mortality among women worldwide. Existing human papillomavirus (HPV) detection methods, such as PCR and immunohistochemistry (IHC), face barriers related to cost, infrastructure, and accessibility. Loop-mediated isothermal amplification (LAMP), a rapid, thermocycler-free nucleic acid amplification technique, combined with lateral flow dipstick (LFD) readout, enables simple, visual DNA detection. Objectives: This study developed and evaluated a novel LAMP-LFD assay to improve the detection of high-risk HPV16/18 in clinical specimens, with the aim of providing a rapid, sensitive, and user-friendly diagnostic tool for use in local healthcare settings. Methods: Cervical specimens were collected from women attending a gynecology clinic who were clinically suspected of having HPV16/18 infection, and DNA was extracted. HPV16/18 presence was initially confirmed by real-time PCR, which served as the reference standard for HPV16/18 detection. Subsequently, LAMP reactions using HPV16/18-specific primers were performed, and amplification products were detected using a molecular LFD system with gold-labeled antibodies. The same DNA samples were then analyzed using the LAMP-LFD assay. The sensitivity and specificity of the LAMP-LFD assay were compared with those of standard PCR methods. Diagnostic performance (sensitivity, specificity, predictive values, accuracy, and Cohen's kappa) was calculated by comparing LAMP-LFD results with real-time PCR. Included samples had adequate volume and acceptable DNA purity (A260/280 ratio: 1.8 - 2). All participants provided written informed consent. Exclusion criteria included sample contamination, insufficient volume, low-quality DNA, lack of signed consent, or failure to meet quality control standards to ensure sample integrity and reproducibility. Agreement between the LAMP-LFD assay and PCR was assessed using Cohen’s kappa coefficient, with 95% confidence intervals calculated. Results: Among the 50 clinical specimens, real-time PCR identified 20 HPV-positive and 30 HPV-negative specimens. Compared with PCR, the LAMP-LFD assay detected all PCR-positive samples but yielded two false-positive results for HPV16, resulting in high sensitivity (100%) and good specificity (93.3%). The specificity of the LAMP-LFD assay was also high, with minimal cross-reactivity observed between HPV16 and HPV18 targets. Compared with conventional PCR, the LAMP-LFD assay provided a faster turnaround time, required less specialized equipment, and was suitable for point-of-care applications. The sensitivity of LAMP is similar to or better than that of PCR (101 to 103 copies). LAMP specificity varies (67.5%-99.2%) and can be lower than that of PCR. Overall, the LAMP-LFD assay demonstrated 100% sensitivity and 93.3% specificity compared with real-time PCR. Conclusions: The developed LAMP-LFD assay is a rapid, sensitive, and user-friendly method for detecting high-risk HPV16 and HPV18 genotypes in clinical specimens. This approach has the potential to enhance HPV screening and cervical cancer prevention, particularly in resource-limited settings where access to conventional molecular diagnostics is restricted. The implementation of LAMP-LFD technology could facilitate timely diagnosis and management of HPV-associated diseases in local hospitals and field studies.
- 15 May 2026
- Published by Elsevier in Experimental Hematology
- Vol. 160, 105444
CD20-targeted immunotherapies in B-cell malignancies: mechanistic and clinical advances
- 15 May 2026
- Published by Elsevier in Experimental Hematology
- Vol. 160, 105444
CD20-targeted immunotherapies in B-cell malignancies: mechanistic and clinical advances
- 20 December 2025
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
Galangin’s Therapeutic Potential in Retinoblastoma: Inducing Apoptosis and Modulating RB Protein and Some MicroRNAs
Retinoblastoma is a type of cancer that develops in the retina, mainly affecting infants and young children under five years old. Research indicates that microRNAs (miRNAs) can either promote or suppress cancer, significantly impacting its development. Galangin exhibits potential anticancer effects, but further research is necessary to confirm its benefits. In this study, the MTT assay was used to assess cell viability. Changes in microRNA expression were analyzed using real-time PCR. The apoptotic effect of galangin was determined using flow cytometry. Changes in RB protein expression due to galangin treatment were determined using Western blotting. A t-test and 2-ΔΔCT were used for data analysis. Statistical significance was considered at P < 0.05. An IC50 of 13.08 μM was determined for the 48-hour MTT assay. Galangin treatment decreased the expression of miR-106a-5p by about 1.41-fold (P value: 0.0375). An about 1.11-fold increase was also observed for mir-519a-3p (P value: 0.0207). The change in miR-192-5p expression was insignificant (P value: 0.4677). A decrease of approximately 1.87-fold was also shown for miR-21-5p (P value: 0.0072). The apoptotic effect of galangin at the IC50 concentration and a dose of 26 µM was 34.30% and 26.70%, respectively. RB protein expression increased 2.66-fold approximately (P value: 0.0045). Our study showed that galangin has an apoptosis-inducing effect in Y79 cell lines. The apoptosis-inducing effect can be dose-dependent and can be reduced by increasing the dose. The increase in RB protein due to galangin treatment is accompanied by an increase in apoptosis. Galangin also affects the expression of miR-106a-5p, miR-519a-3p, and miR-21-5p.
- 20 December 2025
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
Galangin’s Therapeutic Potential in Retinoblastoma: Inducing Apoptosis and Modulating RB Protein and Some MicroRNAs
Retinoblastoma is a type of cancer that develops in the retina, mainly affecting infants and young children under five years old. Research indicates that microRNAs (miRNAs) can either promote or suppress cancer, significantly impacting its development. Galangin exhibits potential anticancer effects, but further research is necessary to confirm its benefits. In this study, the MTT assay was used to assess cell viability. Changes in microRNA expression were analyzed using real-time PCR. The apoptotic effect of galangin was determined using flow cytometry. Changes in RB protein expression due to galangin treatment were determined using Western blotting. A t-test and 2-ΔΔCT were used for data analysis. Statistical significance was considered at P < 0.05. An IC50 of 13.08 μM was determined for the 48-hour MTT assay. Galangin treatment decreased the expression of miR-106a-5p by about 1.41-fold (P value: 0.0375). An about 1.11-fold increase was also observed for mir-519a-3p (P value: 0.0207). The change in miR-192-5p expression was insignificant (P value: 0.4677). A decrease of approximately 1.87-fold was also shown for miR-21-5p (P value: 0.0072). The apoptotic effect of galangin at the IC50 concentration and a dose of 26 µM was 34.30% and 26.70%, respectively. RB protein expression increased 2.66-fold approximately (P value: 0.0045). Our study showed that galangin has an apoptosis-inducing effect in Y79 cell lines. The apoptosis-inducing effect can be dose-dependent and can be reduced by increasing the dose. The increase in RB protein due to galangin treatment is accompanied by an increase in apoptosis. Galangin also affects the expression of miR-106a-5p, miR-519a-3p, and miR-21-5p.
- Open Access
- 12 February 2025
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 15 (1) , 107-122
Targeted Delivery of Bortezomib Using Retinoid-Based Nanoparticle: Modulating Liver Fibrosis through the TGF-β1/Smad3 Pathway
Purpose: Hepatic stellate cells (HSCs) play a crucial role in fibrosis progression. we have developed a targeted delivery approach using A-functionalized nanoparticles for Bortezomib(BTZ) specifically for activated HSCs in a mouse model of liver fibrosis. Methods: The emulsion solvent evaporation method was used to form NPs targeted with Vit A. The characterization of NPs was approved with FTIR, NMR, DLS, and SEM. Also, the biodistribution of NPs inside mice bodies was conducted via fluorescent drug. the cytotoxicity of NPs evaluated in different dose in vitro test. Compared to control groups, a serological evaluation, molecular examination and protein expression were performed based on BRZ's impact on fibrotic index on model mice after treatment with targeted NPs loaded with BTZ. Results: Characterization of synthesized targeted NPs containing BTZ through DLS, XRD and FT-IR showed that the size of NPs was optimum and drug was entraped inside of NPs successfully. Biodistribution of engineered targeted nanoparticles incorporating BTZ in mice showed a gradual tendency of NPs in the liver zone. Moreover, mice treated with vitamin A-targeted containing BTZ showed decreased expression of collagen I, collagen III, and α-SMA; also, the level of expression in TGF-β1/Smad3 and NF-κB genes suppressed in mice treated with NPs entrapped Bortezomib. In line with these results, histopathologic and serological results showed significant exacerbation in non-target and drug-free nanoparticle-treated mice. The best result was seen in mice treated with targeted Bortezomib. Conclusion: Bortezomib, in low amounts entrapped in targeted NPc, could ameliorate the fibrotic index in mice models.
- 12 February 2025
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 15 (1) , 107-122
Open AccessTargeted Delivery of Bortezomib Using Retinoid-Based Nanoparticle: Modulating Liver Fibrosis through the TGF-β1/Smad3 Pathway
Purpose: Hepatic stellate cells (HSCs) play a crucial role in fibrosis progression. we have developed a targeted delivery approach using A-functionalized nanoparticles for Bortezomib(BTZ) specifically for activated HSCs in a mouse model of liver fibrosis. Methods: The emulsion solvent evaporation method was used to form NPs targeted with Vit A. The characterization of NPs was approved with FTIR, NMR, DLS, and SEM. Also, the biodistribution of NPs inside mice bodies was conducted via fluorescent drug. the cytotoxicity of NPs evaluated in different dose in vitro test. Compared to control groups, a serological evaluation, molecular examination and protein expression were performed based on BRZ's impact on fibrotic index on model mice after treatment with targeted NPs loaded with BTZ. Results: Characterization of synthesized targeted NPs containing BTZ through DLS, XRD and FT-IR showed that the size of NPs was optimum and drug was entraped inside of NPs successfully. Biodistribution of engineered targeted nanoparticles incorporating BTZ in mice showed a gradual tendency of NPs in the liver zone. Moreover, mice treated with vitamin A-targeted containing BTZ showed decreased expression of collagen I, collagen III, and α-SMA; also, the level of expression in TGF-β1/Smad3 and NF-κB genes suppressed in mice treated with NPs entrapped Bortezomib. In line with these results, histopathologic and serological results showed significant exacerbation in non-target and drug-free nanoparticle-treated mice. The best result was seen in mice treated with targeted Bortezomib. Conclusion: Bortezomib, in low amounts entrapped in targeted NPc, could ameliorate the fibrotic index in mice models.
- Open Access
- 7 February 2025
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 16 (1) , 1-17
Mitochondrial transplantation for cardioprotection and induction of angiogenesis in ischemic heart disease
To date, the regenerative potential of mitochondrial transplantation (MT) has been extensively investigated under several pathologies. Among various cardiovascular diseases, ischemic heart disease (IHD), the most prevalent pathological condition in human medicine, is induced by coronary artery narrowing, or occlusion, leading to bulk necrotic changes and fibrosis within the myocardium. Data associated with the pro-angiogenic activity of mitochondria have not been completely elucidated in terms of cardiac tissue regeneration. Here, we aimed to highlight the recent studies and advantages related to the application of mitochondrial mass in the ischemic myocardium. How and by which mechanisms, mitochondria can reduce aberrant myocardial tissue remodeling via different pathways such as angiogenesis and de novo blood formation was discussed in detail. We hope that data from the current review article help us understand the molecular and cellular mechanisms by which transplanted mitochondria exert their regenerative properties in the ischemic myocardium.
- 7 February 2025
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 16 (1) , 1-17
Open AccessMitochondrial transplantation for cardioprotection and induction of angiogenesis in ischemic heart disease
To date, the regenerative potential of mitochondrial transplantation (MT) has been extensively investigated under several pathologies. Among various cardiovascular diseases, ischemic heart disease (IHD), the most prevalent pathological condition in human medicine, is induced by coronary artery narrowing, or occlusion, leading to bulk necrotic changes and fibrosis within the myocardium. Data associated with the pro-angiogenic activity of mitochondria have not been completely elucidated in terms of cardiac tissue regeneration. Here, we aimed to highlight the recent studies and advantages related to the application of mitochondrial mass in the ischemic myocardium. How and by which mechanisms, mitochondria can reduce aberrant myocardial tissue remodeling via different pathways such as angiogenesis and de novo blood formation was discussed in detail. We hope that data from the current review article help us understand the molecular and cellular mechanisms by which transplanted mitochondria exert their regenerative properties in the ischemic myocardium.
- 25 January 2025
- Published by Springer Nature in Biochemical Genetics
- Vol. 63 (2) , 1176-1197
MicroRNAs' Significance in Retinoblastoma Diagnosis and Treatment: The Little Heroes
One in 16, 000 live births is affected by the retinal tumor RB (retinoblastoma), which is frequently found in a child’s early years. Both of the RB1 alleles that have been locally mutated in the affected retina are present in 60 percent of cases. Retinoblastoma (RB) can be detected using a variety of techniques, including imaging of the brain and orbits, eye examinations under anesthesia (EUAs), and the discovery of cell-free tumor DNA in samples of aqueous humor or plasma. In addition to the conventional surgical, chemotherapy, and radiotherapy approaches to treating retinoblastoma, new approaches have also been developed. Oncogenes, genes of tumor suppressors, and other molecular elements involved in cell growth and division interact complexly during the pathogenesis of retinoblastoma. The development of new therapies depends on comprehending the function of these molecular components. As a small class of non-coding RNAs capable of altering gene expression, microRNAs (miRNA) are understood to represent potential targets for the treatment of cancer. This study aimed to describe the changes in microRNA expression in some types of cancer, with a particular focus on retinoblastoma. Graphical Abstract Molecular mechanism of microRNA targeting: a promising approach for retinoblastoma diagnosis and treatment. The pathogenesis of retinoblastoma involves a complex interaction between tumor suppressor genes, oncogene, and other molecular components involved in cell growth and division
- 25 January 2025
- Published by Springer Nature in Biochemical Genetics
- Vol. 63 (2) , 1176-1197
MicroRNAs' Significance in Retinoblastoma Diagnosis and Treatment: The Little Heroes
One in 16, 000 live births is affected by the retinal tumor RB (retinoblastoma), which is frequently found in a child’s early years. Both of the RB1 alleles that have been locally mutated in the affected retina are present in 60 percent of cases. Retinoblastoma (RB) can be detected using a variety of techniques, including imaging of the brain and orbits, eye examinations under anesthesia (EUAs), and the discovery of cell-free tumor DNA in samples of aqueous humor or plasma. In addition to the conventional surgical, chemotherapy, and radiotherapy approaches to treating retinoblastoma, new approaches have also been developed. Oncogenes, genes of tumor suppressors, and other molecular elements involved in cell growth and division interact complexly during the pathogenesis of retinoblastoma. The development of new therapies depends on comprehending the function of these molecular components. As a small class of non-coding RNAs capable of altering gene expression, microRNAs (miRNA) are understood to represent potential targets for the treatment of cancer. This study aimed to describe the changes in microRNA expression in some types of cancer, with a particular focus on retinoblastoma. Graphical Abstract Molecular mechanism of microRNA targeting: a promising approach for retinoblastoma diagnosis and treatment. The pathogenesis of retinoblastoma involves a complex interaction between tumor suppressor genes, oncogene, and other molecular components involved in cell growth and division
- Open Access
- 24 November 2024
- Published by CMB Association in Cellular and Molecular Biology
- Vol. 70 (10) , 117-133
Targeting key players in lipid biosynthesis for NAFLD and NASH treatment
Undoubtedly, nonalcoholic fatty liver disease (NAFLD) is widely recognized as one of the most prevalent liver diseases worldwide, encompassing a broad spectrum from simple steatosis to the most advanced stage of nonalcoholic steatohepatitis (NASH). However, effective treatments for NAFLD and NASH have not yet been clearly defined. Using appropriate terms such as "Nonalcoholic Fatty Liver Disease", "NAFLD treatment", “Lipid metabolism”, “lipid biosynthesis”, autophagy “bFGF” and TFG-b” apoptosis, we searched for relevant articles in the PubMed and Scopus databases. This review will discuss the role of the most important players in controlling lipid biosynthesis and lipid metabolism imperfection, which leads to NASH and NAFLD. Furthermore, potential pharmacological agents for targeting molecules and signaling pathways involved in liver inflammation, fibrosis, and cell death are also discussed.
- 24 November 2024
- Published by CMB Association in Cellular and Molecular Biology
- Vol. 70 (10) , 117-133
Open AccessTargeting key players in lipid biosynthesis for NAFLD and NASH treatment
Undoubtedly, nonalcoholic fatty liver disease (NAFLD) is widely recognized as one of the most prevalent liver diseases worldwide, encompassing a broad spectrum from simple steatosis to the most advanced stage of nonalcoholic steatohepatitis (NASH). However, effective treatments for NAFLD and NASH have not yet been clearly defined. Using appropriate terms such as "Nonalcoholic Fatty Liver Disease", "NAFLD treatment", “Lipid metabolism”, “lipid biosynthesis”, autophagy “bFGF” and TFG-b” apoptosis, we searched for relevant articles in the PubMed and Scopus databases. This review will discuss the role of the most important players in controlling lipid biosynthesis and lipid metabolism imperfection, which leads to NASH and NAFLD. Furthermore, potential pharmacological agents for targeting molecules and signaling pathways involved in liver inflammation, fibrosis, and cell death are also discussed.
- 2 September 2024
- Published by Springer Nature in Functional & Integrative Genomics
- Vol. 24 (5) , 1-24
Modulatory effects of miRNAs in doxorubicin resistance: A mechanistic view
MicroRNAs (miRNAs) are a group of small non-coding RNAs and play an important role in controlling vital biological processes, including cell cycle control, apoptosis, metabolism, and development and differentiation, which lead to various diseases such as neurological, metabolic disorders, and cancer. Chemotherapy consider as gold treatment approaches for cancer patients. However, chemotherapeutic is one of the main challenges in cancer management. Doxorubicin (DOX) is an anti-cancer drug that interferes with the growth and spread of cancer cells. DOX is used to treat various types of cancer, including breast, nervous tissue, bladder, stomach, ovary, thyroid, lung, bone, muscle, joint and soft tissue cancers. Also recently, miRNAs have been identified as master regulators of specific genes responsible for the mechanisms that initiate chemical resistance. miRNAs have a regulatory effect on chemotherapy resistance through the regulation of apoptosis process. Also, the effect of miRNAs p53 gene as a key tumor suppressor was confirmed via studies. miRNAs can affect main biological pathways include PI3K pathway. This review aimed to present the current understanding of the mechanisms and effects of miRNAs on apoptosis, p53 and PTEN/PI3K/Akt signaling pathway related to DOX resistance. Graphical Abstract miRNAs involve in DOX resistance according to effecting pathways.
- 2 September 2024
- Published by Springer Nature in Functional & Integrative Genomics
- Vol. 24 (5) , 1-24
Modulatory effects of miRNAs in doxorubicin resistance: A mechanistic view
MicroRNAs (miRNAs) are a group of small non-coding RNAs and play an important role in controlling vital biological processes, including cell cycle control, apoptosis, metabolism, and development and differentiation, which lead to various diseases such as neurological, metabolic disorders, and cancer. Chemotherapy consider as gold treatment approaches for cancer patients. However, chemotherapeutic is one of the main challenges in cancer management. Doxorubicin (DOX) is an anti-cancer drug that interferes with the growth and spread of cancer cells. DOX is used to treat various types of cancer, including breast, nervous tissue, bladder, stomach, ovary, thyroid, lung, bone, muscle, joint and soft tissue cancers. Also recently, miRNAs have been identified as master regulators of specific genes responsible for the mechanisms that initiate chemical resistance. miRNAs have a regulatory effect on chemotherapy resistance through the regulation of apoptosis process. Also, the effect of miRNAs p53 gene as a key tumor suppressor was confirmed via studies. miRNAs can affect main biological pathways include PI3K pathway. This review aimed to present the current understanding of the mechanisms and effects of miRNAs on apoptosis, p53 and PTEN/PI3K/Akt signaling pathway related to DOX resistance. Graphical Abstract miRNAs involve in DOX resistance according to effecting pathways.